Literature DB >> 11485583

The investigation of nasal septal perforations and ulcers.

I I Diamantopoulos1, N S Jones.   

Abstract

This is a retrospective review of 74 consecutive patients who presented with a nasal septal perforation or ulcer. The aim of this study was to evaluate the contribution of the investigations used to identify the pathology underlying their septal perforation or ulcer. In the majority of cases there was an anterior (85 per cent) smooth, well-circumscribed septal lesion with an occasional bleeding point. Seventy-seven per cent were less than two cm in diameter. The primary presenting symptom was intermittent epistaxis, with the exception of patients with granulomatous disease, who presented more frequently with nasal obstruction. Thirty-five patients (47 per cent) were idiopathic, 29 (39 per cent) traumatic, eight (11 per cent) inflammatory and two (three per cent) infectious. The nasal septum was biopsied in 71 cases, and histology showed non-specific or non-diagnostic findings in 39 (55 per cent), chronic inflammation in 12 (17 per cent), acute inflammation in six (eight per cent), acute to chronic inflammation in four (six per cent) and histological changes consistent with trauma in nine (13 per cent). The anti-neutrophil cytoplasmic antibody test (ANCA) successfully identified six patients with Wegener's granulomatosis, and the angiotensin converting enzyme test (ACE) supported a clinical diagnosis of sarcoidosis in one patient. The remaining investigation methods (CRP, ESR, chest radiograph, biochemistry and coagulation screen) did not contribute to the diagnosis. In this study, the appearance of a nasal septal perforation or ulcer or its location did not predict the clinical diagnosis. A nasal septal bopsy did not significantly contribute toward the clinical diagnosis. On the basis of these findings, a biopsy of a septal perforation or ulcer is unlikely to contribute to the management of patients unless the supportive tests of ANCA or ACE are abnormal or unless malignancy is suspected. This conclusion is restricted to the management of septal perforations as we have found nasal biopsies of polyps of other lesions to be of value.

Entities:  

Mesh:

Year:  2001        PMID: 11485583     DOI: 10.1258/0022215011908441

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  16 in total

Review 1.  Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance.

Authors:  Judi Anne B Ramiscal; Aminah Jatoi
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

2.  Risk of nasal septal perforation following septoplasty in patients with allergic rhinitis.

Authors:  Ozgul Topal; Sakir Bilge Celik; Seyra Erbek; Selim S Erbek
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-02       Impact factor: 2.503

3.  Increased histopathological yield for granulomatosis with polyangiitis based on nasal endoscopy of suspected active lesions.

Authors:  Olga Beltrán Rodríguez-Cabo; Edgardo Reyes; Jorge Rojas-Serrano; Luis Felipe Flores-Suárez
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-11       Impact factor: 2.503

Review 4.  Nasoseptal Perforation: from Etiology to Treatment.

Authors:  Carla Pereira; Alfonso Santamaría; Cristobal Langdon; Mauricio López-Chacón; José Hernández-Rodríguez; Isam Alobid
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-05       Impact factor: 4.806

5.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

6.  Asymptomatic vs symptomatic septal perforations: a computational fluid dynamics examination.

Authors:  Chengyu Li; Guillermo Maza; Alexander A Farag; Jillian P Krebs; Bhakthi Deshpande; Bradley A Otto; Kai Zhao
Journal:  Int Forum Allergy Rhinol       Date:  2019-05-29       Impact factor: 3.858

7.  Nasal septal perforation in a patient with subclinical celiac disease: a possible new association.

Authors:  A Medina-Banegas; F A Pastor-Quirante; J Osete-Albaladejo; E López-Meseguer; F López-Andreu
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-10-22       Impact factor: 2.503

Review 8.  Biomarkers in ANCA-Associated Vasculitis: Potential Pitfalls and Future Prospects.

Authors:  Adam D Morris; Anthony W Rowbottom; Francis L Martin; Alexander Woywodt; Ajay P Dhaygude
Journal:  Kidney360       Date:  2021-01-19

9.  Nasal septum perforation and bevacizumab.

Authors:  Derek G Power; Nancy E Kemeny
Journal:  Med Oncol       Date:  2010-03-06       Impact factor: 3.738

10.  Modeling nasal physiology changes due to septal perforations.

Authors:  Daniel E Cannon; Dennis O Frank; Julia S Kimbell; David M Poetker; John S Rhee
Journal:  Otolaryngol Head Neck Surg       Date:  2013-01-11       Impact factor: 3.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.